Recursion Pharmaceuticals and Exscientia, AI-driven drug discovery firms, are merging to accelerate medicine discovery.
Recursion Pharmaceuticals and Exscientia, AI-powered drug discovery companies, have agreed to merge. The combined company will retain the Recursion name and continue trading on NASDAQ. The merged entity aims to accelerate the discovery and translation of high-quality medicines by leveraging AI, precision chemistry design, and automated synthesis technologies. The combined company is expected to read out approximately ten clinical trials in the next 18 months, with potential peak sales opportunities of over $1 billion annually. The merger will result in approximately $100 million in annual synergies and extend the company's runway into 2027. The combined company will focus on first-in-class and best-in-class drug candidates within oncology, rare disease, and infectious disease.